Latest Breaking News On - Novartis pharmaceuticals canada inc - Page 1 : comparemela.com

MorphoSys stock gains after Novartis discloses all tender offer conditions were met

MorphoSys stock gains after Novartis discloses all tender offer conditions were met
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Novartis pharmaceuticals canada incNovartis pharmaceuticals canadaStock editorial

Clozapine: Once-Daily or Divided Dosing?

Compared with divided dosing, patients with once-daily dosing had shorter illness duration and better clinical outcomes.

United statesJ clin psychopharmacolAugusta universityHealth behaviorNational institute of mental healthInstitute of mental healthStanley medical research instituteDepartment of psychiatryNovartis pharmaceuticals canada incMental healthNegative syndrome scaleOccupational functioning assessment scaleEffects assessedNational instituteStanley medical researchActa psychiatr

INNODEM NEUROSCIENCES ETNAtm-MS OBTAINS HEALTH CANADA S APPROVAL

INNODEM NEUROSCIENCES ETNAtm-MS OBTAINS HEALTH CANADA S APPROVAL
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Erin keithInnodem neurosciencesMarc reevesNeuroscience at novartis pharmaceuticals canada incHealth canadaNovartis pharmaceuticals canada incEye tracking neurological assessmentMultiple sclerosisExpanded disability status scalePad proChief business officerChief executive officerNovartis pharmaceuticals canadaVice president

INNODEM NEUROSCIENCES ETNA™-MS OBTAINS HEALTH CANADA S APPROVAL

Innodem Neurosciences, a leading digital health and AI company, announced today that its ETNA™-MS has been cleared for commercial use by Health Canada. The Eye Tracking Neurological Assessment for Multiple Sclerosis (ETNA™-MS) is a software as a medical device (SaMD, Class II) intended to administer a non-invasive test and provide an Expanded Disability Status Scale (EDSS) score in the range between 1.0 and 4.5 for use in tracking disease progression in MS patients.

Innodem neurosciencesMarc reevesErin keithNovartis pharmaceuticals canada incNeuroscience at novartis pharmaceuticals canada incPad proChief business officerChief executive officerNovartis pharmaceuticals canadaVice presidentEye tracking neurological assessmentEye movementMedical deviceHealth canadaDss scoreI company

First came Florida Now Colorado and others seek to import Canadian drugs

Increasing number of states see securing imports from Canada as a key step toward lowering the price of drugs in the U.S.

United statesUjjal dosanjhDavid renwickJaquez lewisMark hollandRita moutinhoSonya jaquez lewisChristopher aounClaudja josephHuman servicesColorado departmentNovartis pharmaceuticals canada incDepartment of healthHealth canadaDrug administrationLog increate free